|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
6/12/2008 9:42:49 AM
YONKERS, NY--(Marketwire - June 12, 2008) - Advanced Viral Research Corp. (OTCBB: ADVR), a cancer therapeutics company, announced today that it had reached an agreement with YA Global Investments, L.P. to amend the terms of its previously announced Securities Purchase Agreement dated July 24, 2007. The amendment provides for the sale of the remaining $1,250,000 principal amount of the Company's 9% Series B Convertible Debentures (the "Debentures") in four equal installments, the first of which closed on June 6, 2008. The Debentures have a conversion price equal to the lesser of $0.0262 or 95% of the lowest volume weighted average price of the Company's common stock during the thirty consecutive trading days immediately preceding the applicable conversion date.
|
|
|
|
|
|
|
|
|
|
|